Thrivent Financial for Lutherans Has $1.11 Million Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Thrivent Financial for Lutherans trimmed its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 42.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,640 shares of the company’s stock after selling 28,224 shares during the quarter. Thrivent Financial for Lutherans owned about 0.08% of Pacira BioSciences worth $1,105,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of PCRX. Doma Perpetual Capital Management LLC acquired a new stake in shares of Pacira BioSciences in the fourth quarter worth $6,286,000. Frontier Capital Management Co. LLC lifted its stake in shares of Pacira BioSciences by 15.8% in the fourth quarter. Frontier Capital Management Co. LLC now owns 2,084,542 shares of the company’s stock worth $70,332,000 after buying an additional 285,045 shares during the last quarter. Cobalt Capital Management Inc. acquired a new stake in shares of Pacira BioSciences in the fourth quarter worth $3,037,000. Wellington Management Group LLP raised its stake in Pacira BioSciences by 4.4% during the 4th quarter. Wellington Management Group LLP now owns 327,606 shares of the company’s stock valued at $11,053,000 after purchasing an additional 13,696 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Pacira BioSciences by 2.9% during the 4th quarter. Vanguard Group Inc. now owns 5,098,424 shares of the company’s stock valued at $172,021,000 after purchasing an additional 141,719 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PCRX has been the subject of several research analyst reports. Needham & Company LLC cut their target price on shares of Pacira BioSciences from $43.00 to $22.00 and set a “buy” rating for the company in a research note on Monday, August 12th. HC Wainwright cut their target price on shares of Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Piper Sandler cut shares of Pacira BioSciences from an “overweight” rating to a “neutral” rating and cut their target price for the company from $42.00 to $11.00 in a research note on Monday, August 12th. StockNews.com cut shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 12th. Finally, JPMorgan Chase & Co. reissued an “underweight” rating and issued a $10.00 price target (down previously from $45.00) on shares of Pacira BioSciences in a report on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $24.20.

Pacira BioSciences Stock Up 3.9 %

PCRX opened at $16.52 on Friday. The firm’s 50-day simple moving average is $15.40 and its 200-day simple moving average is $22.93. The company has a debt-to-equity ratio of 0.67, a quick ratio of 5.70 and a current ratio of 6.82. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $35.95. The firm has a market cap of $768.71 million, a price-to-earnings ratio of 11.55 and a beta of 0.84.

Pacira BioSciences (NASDAQ:PCRX) last posted its earnings results on Tuesday, July 30th. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.11. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The business had revenue of $178.02 million for the quarter, compared to analyst estimates of $173.31 million. Equities research analysts anticipate that Pacira BioSciences, Inc. will post 2.24 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Frank D. Lee purchased 8,264 shares of Pacira BioSciences stock in a transaction that occurred on Monday, August 12th. The shares were acquired at an average price of $12.10 per share, for a total transaction of $99,994.40. Following the transaction, the chief executive officer now directly owns 107,784 shares in the company, valued at approximately $1,304,186.40. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have purchased a total of 11,176 shares of company stock worth $136,240 in the last 90 days. Corporate insiders own 6.40% of the company’s stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.